NextGen launches new assay; Massachusetts puts $28M into life sciences innovation;

 @FierceMedDev: As the debate over the device tax continues, a hospital group warns that devicemakers might try to game the system: Story | Follow @FierceMedDev

 @MarkHFierce: Folks, there's still time to submit your nominations for the FierceMedicalDevices Fierce 15 private device developers. Survey | Follow @MarkHFierce

 @DamianFierce: Rivals St. Jude and Medtronic are at it again, this time over study results for $STJ's EnligHTN More | Follow @DamianFierce

> NextGen, which has operations in the U.K. and Michigan, is launching a new assay designed to identify diagnostic biomarkers in brain disorders. Release

> The Penn State Research Foundation has inked a deal with device firm Minnetronix to provide wireless energy technology for left ventricular assist devices. Story

> Embrace is using its partnership with GE Healthcare ($GE) to provide affordable infant warmers to the developing world, and the company is partnering with NGOs around the world to get the product into needy hands. Report

> Massachusetts is planning to bolster its life sciences industry with a $28 million biotech facility in Fall River, managed by UMass. News

> CBS Atlanta has taken a closer look at the effects of 2010's recall of the DePuy's ASR XL hip replacement. Item

Pharma News

 @FiercePharma: Momenta tops Boston Globe list of best-performing companies. Generic Lovenox made the difference. Story | Follow @FiercePharma

 @EricPFierce: What leads many employers' concerns for drug benefits? The huge jump in specialty drug expense for starters. Piece | Follow @EricPFierce

> Generic floodgates open for Plavix in U.S. Article

> Warner Chilcott sues Watson to stop generic contraceptive. News

> Employers eye costs of specialty drugs. Story

> Drugmakers rail against India's move toward price controls. More

Biotech News

 @FierceBiotech: Gene therapy = fountain of youth in mice. Article | Follow @FierceBiotech

 @RyanMFierce: Osiris got a "first" ever nod for a stem-cell drug in Canada, but the business implications appear small. More | Follow @RyanMFierce

> The R&D revolution wants you. More

> New cloud hovers over class of 'good cholesterol' drugs. Story

> Kleiner Perkins to back early-stage biotechs with $525M fund. Article

> Allergan to enlist new hires in R&D expansion. News

> Canada hands Osiris historic approval for stem-cell drug. Report